Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionMacquarie Group Ltd
Latest Disclosed Ownership16,047 shares
Latest Disclosed Value $ 5,309,471
Macquarie Group Ltd reports 36.53% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Macquarie Group Ltd filed a 13F-HR form disclosing ownership of 16,047 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $4,584,628 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 25,281 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -36.53% during the quarter. The current value of the position is $4,040,635 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,047 -9,234 -36.53 5,309 -47.18 0.0247
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,281 -623,063 -96.10 10,053 -96.60 0.0439
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 648,344 48,233 8.04 295,645 51.08 0.3451
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 600,111 527,519 726.69 195,691 898.42 0.2400
2025-08-14 2025-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 72,592 11,928 19.66 19,601 37.31 0.0243
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 72,592 11,928 19,601 0.0160
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,664 -11,952 -16.46 14,275 -28.53 0.0173
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 72,616 13,161 22.14 19,971 38.24 0.0216
2024-08-09 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 59,455 3,548 6.35 14,447 72.91 0.0166
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,907 8,890 18.91 8,355 -7.16 0.0095
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,017 1,111 2.42 9,000 10.70 0.0104
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,906 882 1.96 8,130 -4.94 0.0102
2023-10-27 2023-06-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 45,024 -705 -1.54 8,552 -6.65 0.0098
2023-10-12 2023-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 45,024 -705 8,552 0.0086
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,024 -705 8,552 0.0087
2023-06-01 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 45,729 511 1.13 9,160 -14.75 0.0109
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,729 511 9,160 0.0084
2023-02-21 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,218 934 2.11 10,746 21.22 0.0127
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,284 1,352 3.15 8,864 41.55 0.0109
2022-08-17 2022-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 42,932 -279 -0.65 6,262 -11.25 0.0070
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,932 -279 6,262 0.0022
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,211 96 0.22 7,056 -3.50 0.0054
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,115 -10,478 -19.55 7,312 -27.74 0.0061
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 53,593 0 0.00 10,119 11.38 0.0086
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 53,593 100 0.19 9,085 20.28 0.0075
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 53,493 10,198 23.55 7,553 34.23 0.0107
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,295 -842 -1.91 5,627 -12.43 0.0082
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,137 -10,610 -19.38 6,426 -20.74 0.0109
2020-08-11 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,747 -1,556 -2.76 8,108 32.31 0.0140
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,303 -2,875 -4.86 6,128 -10.09 0.0126
2020-03-18 2019-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 59,178 103 0.17 6,816 43.46 0.0097
2020-02-28 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 59,178 0 6,816 0.0098
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 59,178 103 6,816 8,553.5024
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 59,075 -3,213 -5.16 4,751 5.11 0.0080
2019-11-06 2019-06-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 62,288 4,215 7.26 4,520 -16.71 0.0076
2019-09-24 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 62,288 0 4,520 0.0077
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 62,288 4,215 4,520
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 58,073 220 0.38 5,427 28.66 0.0093
2019-02-15 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,853 438 0.76 4,218 -16.06 0.0082
2018-11-15 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,415 784 1.38 5,025 -9.91 0.0082
2019-03-21 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 56,631 13,747 32.06 5,578 9.22 0.0096
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,631 13,747 5,578
2018-05-11 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,884 1,958 4.78 5,107 -1.79 0.0093
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,926 27,914 214.53 5,200 240.09 0.0092
2017-11-08 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,012 -2,649 -16.91 1,529 22.42 0.0027
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,661 -1,608 -9.31 1,249 41.13 0.0023
2017-05-15 2017-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 17,269 -486 -2.74 885 33.08 0.0016
2017-03-30 2016-12-31 13F/A-1 Alnylam Pharmaceuticals COMMON 02043Q107 17,755 1,614 10.00 665 -39.21 0.0013
2017-02-15 2016-12-31 13F Alnylam Pharmaceuticals COMMON 02043Q107 17,755 665
2016-11-15 2016-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 16,141 -4,002 -19.87 1,094 -2.15 0.0021
2016-09-14 2016-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COMMON 02043Q107 20,143 19,243 2,138.11 1,118 1,896.43 0.0022
2016-08-15 2016-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 20,143 1,118
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 900 0 0.00 56 -34.12 0.0001
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 900 0 0.00 85 18.06 0.0002
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 900 -14,384 -94.11 72 -96.07 0.0002
2015-08-21 2015-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 15,284 -4,587 -23.08 1,832 -11.71 0.0036
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 15,284 1,832
2015-05-18 2015-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 19,871 -6,167 -23.68 2,075 -17.85 0.0041
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 26,038 -1,994 -7.11 2,526 15.40 0.0052
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 28,032 -2,000 -6.66 2,189 15.39 0.0047
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 30,032 2,828 10.40 1,897 3.89 0.0042
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS Common 02043Q107 27,204 -15,646 -36.51 1,826 -33.77 0.0032
2014-02-14 2013-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 42,850 16,759 64.23 2,757 65.09 0.0049
2013-11-14 2013-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 26,091 8,091 44.95 1,670 199.28 0.0033
2013-08-16 2013-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COMMON 02043Q107 18,000 18,000 558 0.0012
2013-08-14 2013-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 18,000 558 0.0012
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.